Skip to the content

pharmaceutical daily

Pharmaceuticals, Biotechnology and Life Sciences

  • HOME
  • Pharma Business
  • About us
    • Media Kit
    • Privacy Policy
  • Contact
BiondVax Pharmaceuticals enrolls first patients to test flu vaccine candidate
July 8, 2019 Off

BiondVax Pharmaceuticals enrolls first patients to test flu vaccine candidate

By Dino Mustafić

@BiondVax Pharmaceuticals has enrolled first participants in the second cohort of the pivotal, clinical efficacy, Phase 3 trial of the M-001 universal #flu #vaccine candidate.

July 8, 2019 Off

Kraig Biocraft Laboratories to Host Annual Shareholder Meeting

By BusinessWire

ANN ARBOR, Mich.–(BUSINESS WIRE)–$KBLB #KBLB–Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk based fibers, announces…

July 8, 2019 Off

Global Cell-based Assay Market Worth $14Bn in 2018, is Projected to Exceed $23Bn by 2024 – ResearchAndMarkets.com

By BusinessWire

DUBLIN–(BUSINESS WIRE)–The “Cell-based Assay Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2019-2024” report has been added to…

July 8, 2019 Off

Acerus Announces Publication of Study Results Demonstrating Effectiveness of NATESTO® Regardless of Baseline Symptom Severity

By BusinessWire

TORONTO–(BUSINESS WIRE)–Acerus Pharmaceuticals Corporation (TSX: ASP, OTCQB: ASPCF) (“Acerus” or the “Company”) announced today the acceptance of a new manuscript…

July 8, 2019 Off

PhoreMost and inStem Enter Structural Biology Alliance

By BusinessWire

inStem’s Centre for Chemical Biology and Therapeutics to work with PhoreMost to progress selected targets CAMBRIDGE, England–(BUSINESS WIRE)–PhoreMost, the UK-based…

July 8, 2019 Off

Horizon Discovery’s SMARTvector shRNA Technology Deployed in Celyad’s Successful IND Filing for Next-Generation CAR-T Cell Therapy, CYAD-02

By BusinessWire

Phase 1 trial scheduled for early 2020 will be first CAR-T cell therapy clinical trial to employ SMARTvector technology Horizon…

July 8, 2019 Off

Takeda Unveil New Data from the PROPEL Study at ISTH 2019, Reinforcing the Potential Benefit for Personalized Prophylaxis with ADYNOVATE in Severe Hemophilia A

By BusinessWire

– Updated results from the Phase IIIb/IV PROPEL Study show that pharmacokinetic (PK)-driven dosing may be used to achieve FVIII…

July 8, 2019 Off

Takeda Unveil New Data from the PROPEL Study at ISTH 2019, Reinforcing the Potential Benefit for Personalized Prophylaxis with ADYNOVATE in Severe Hemophilia A

By BusinessWire

– Updated results from the Phase IIIb/IV PROPEL Study show that pharmacokinetic (PK)-driven dosing may be used to achieve FVIII…

July 6, 2019 Off

Pierre Fabre and its partner Array BioPharma announce interim analysis results from the BEACON CRC Trial of encorafenib + binimetinib + cetuximab for the treatment of BRAFV600E-mutant metastatic colorectal cancer

By BusinessWire

– Encorafenib combinations (encorafenib + binimetinib + cetuximab together = encorafenib Triplet; encorafenib + cetuximab together = encorafenib Doublet) showed…

July 6, 2019 Off

Sangamo and Pfizer Announce Updated Phase 1/2 Results for SB-525 Investigational Hemophilia A Gene Therapy Showing Sustained Increased Factor VIII Levels

By BusinessWire

The first two patients treated at the 3e13 vg/kg dose level rapidly achieved normal, sustained Factor VIII (FVIII) levels with…

Posts pagination

Previous 1 … 3,026 3,027 3,028 … 3,606 Next

JOIN OUR COMMUNITY

Proudly powered by WordPress | Theme: Envo Magazine